A

Alphatec Spine

Develops and markets spinal surgery solutions

Overview

Alphatec Spine develops and markets implants, instruments, and technologies for spine surgery, including systems for spinal fusion. Its products work by providing implants (cages, screws, plates) and surgical tools, with some offerings integrating imaging or navigation to guide procedures and support healing. It differentiates itself through a broad product portfolio and technology acquisitions (such as SafeOp Surgical) to expand capabilities in navigation and advanced spine care. Its goal is to improve patient outcomes and expand access to effective spine-care solutions by delivering a diverse set of implants, instruments, and technologies for surgeons.

Significant Headcount Growth

Work here?Claim your company

About Alphatec Spine

Simplify's Rating
Why Alphatec Spine is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Healthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Carlsbad, CA

Founded

1990

Get referred to Alphatec Spine

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Q2 2026 revenue reached $213.5 million, up 15% year over year.
  • Adjusted EBITDA rose 53% to $36 million, lifting margin to 17%.
  • May 2026 refinancing extended maturities to 2031 and cut interest expense $6 million.

What critics are saying

  • May 2026 EOS revenue missed expectations; installations failed, triggering a 32% stock drop.
  • Kirby McInerney, Pomerantz, and others investigate potential securities fraud after the May 5 disclosure.
  • With $685 million debt, another EOS stall can force dilutive financing before 2030.

What makes Alphatec Spine unique

  • ATEC combines EOS imaging, Valence robotics, SafeOp neuromonitoring, and patient-specific planning.
  • Tommy Carls joined September 2026 to unify InformatiX across imaging, analytics, and surgery.
  • Its procedural ecosystem ties preoperative planning directly to intraoperative execution.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$987M

Above

Industry Average

Funded Over

10 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Debt Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Disability Insurance
  • Stock Options

Stock Price

Growth & Insights and Company News

6 month growth

6%

1 year growth

6%

2 year growth

6%
Yahoo Finance
Oct 31st, 2026
Alphatec Q3 revenue rises 13% to $221M but guidance cut to $862M on biologics slump

Alphatec Holdings reported third-quarter revenue of $221 million, up 13% year-over-year, but missed expectations and cut its 2026 revenue guidance to about $862 million. Adjusted EBITDA rose 46% to $38 million, a 17% margin. Gross margin improved to 72%, and the company posted positive free cash flow for the fifth straight quarter. It also repaid its remaining 2026 convertible notes. Surgical volumes grew about 20%, and new surgeon growth was about 25%. Weakness came from biologics, which fell $1 million year-over-year, and from slower thoracolumbar procedures amid a softer market. Chief executive officer Pat Miles blamed a lack of sales discipline on biologics and promised tougher enforcement across the sales force.

Yahoo Finance
Oct 29th, 2026
Alphatec posts $5.5M Q3 loss as $221.2M revenue misses forecasts

Alphatec Holdings Inc. reported a third-quarter loss of $5.5 million on Thursday, or 3 cents per share. Adjusted earnings were 9 cents per share. The Carlsbad, California-based medical equipment company posted revenue of $221.2 million, below the $224.3 million that four analysts surveyed by Zacks expected. Alphatec expects full-year revenue of $862 million. Its shares have fallen 46% since the start of the year. They traded at $11.37 in the final minutes on Thursday, down 31% over 12 months.

Yahoo Finance
Oct 18th, 2026
Alphatec shares down 49.6% this year, but DCF model suggests 48% undervaluation

Alphatec Holdings shares have fallen 49.6% so far this year to $10.46, raising the question of whether the spinal surgery company's cash generation supports its valuation. Over the last twelve months, the company's free cash flow was about negative $35 million. Analysts expect it to turn positive and grow, with projections rising from the late 2020s onward. A two-stage discounted cash flow model based on those forecasts puts Alphatec's intrinsic value well above the current price. The headline estimate is that the stock is 48% undervalued. One community narrative on Simply Wall St is more cautious, putting the stock at 13% undervalued. It warns that cost pressures and lower-cost rivals could erode pricing power and margins.

SPINEMarketGroup
Sep 24th, 2026
ATEC appoints Tommy Carls Executive Vice President, Data Intelligence and Strategy.

ATEC appoints Tommy Carls Executive Vice President, Data Intelligence and Strategy. Accomplished spine executive to advance ATEC's InformatiX strategy CARLSBAD, Calif.-(BUSINESS WIRE)-Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced that Thomas "Tommy" Carls has joined the company as Executive Vice President, Data Intelligence and Strategy. Carls will report directly to Chairman and Chief Executive Officer, Pat Miles, and will serve as a member of ATEC's Senior Leadership Team. In this newly created role, Carls will lead ATEC's development and marketing efforts across EOSedge, EOS Insight, data acquisition and analytics, and the broader InformatiX strategy. His mandate is to focus priorities, connect global teams and capabilities, and accelerate an integrated strategy that turns information about each patient and procedure into actionable clinical insight. "I have known and trusted Tommy for nearly 30 years," said Miles. "He has spent his career translating complex clinical needs into technologies that meaningfully advance spine surgery. Tommy is a student of spine. His depth of experience across implants, enabling technologies, imaging, software and clinical strategy makes him uniquely qualified to lead this next phase of our evolution. I am confident Tommy will help us accelerate the use of data and predictive analytics to make spine surgery better informed, more reproducible and personalized." ATEC has assembled a procedural ecosystem spanning EOS imaging, EOS Insight, surgical planning, Valence navigation and robotics, SafeOp neuromonitoring, and patient-specific solutions. By connecting those capabilities through InformatiX, ATEC intends to apply data and predictive analytics to inform decisions before, during and after surgery, improve the reproducibility of surgical execution, and create a learning system that advances spine care over time. Carls brings more than 3 decades of leadership and innovation experience in spine and medical technology. Throughout his career, Carls has helped develop and launch market-leading technologies across spinal implants, enabling technologies, image-guided surgery and robotics. He previously served as Vice President of Product and Clinical at Proprio Vision, where he helped advance an artificial intelligence-enabled surgical navigation platform. Before Proprio, Carls spent more than two decades with Sofamor Danek and Medtronic in numerous executive roles, spanning engineering, product development, marketing and global research and development. He holds more than 80 patents. Carls earned a Bachelor of Science degree in mechanical engineering from Tulane University and a Master of Business Administration from the University of Memphis. "ATEC has assembled a distinctive set of technologies across imaging, procedural planning, navigation and robotics, neuromonitoring, and patient-specific solutions," Carls said. "The opportunity is to connect those capabilities and apply data and predictive analytics, so a patient-specific plan becomes a shared source of truth across the continuum of care. This will inform better decisions, improve execution and create a learning system that advances outcomes over time. I am excited to join Pat and the high-performing ATEC team, to help bring that vision to life." About Alphatec Holdings Inc. ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC's Organic Innovation Machine(TM) is focused on developing new approaches that integrate seamlessly with the Company's expanding InformatiX(TM) platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC's vision is to be the Standard Bearer in Spine. For more information, visit www.atecspine.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Forward-looking statements include, among other things, statements regarding the Company's strategy; the integration of its technologies, teams and capabilities; the use of data and predictive analytics; and the anticipated clinical or commercial benefits of its InformatiX platform and procedural ecosystem. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Important factors include the Company's ability to execute its strategic operating plan, develop and integrate new products and technologies, obtain and maintain regulatory clearances or approvals, achieve surgeon acceptance, protect intellectual property, manage product liability and litigation exposure, and address other risks described in the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contacts. Investor and Media Contact Robert Judd Investor Relations (760) 494-6790 [email protected]

Business Wire
Sep 23rd, 2026
ATEC appoints Tommy Carls to lead data intelligence and InformatiX strategy

Alphatec Holdings has appointed Tommy Carls as executive vice president of data intelligence and strategy. Carls will report to chief executive officer Pat Miles and join the company's senior leadership team. In this newly created role, Carls will lead ATEC's development and marketing efforts across EOSedge, EOS Insight, data acquisition and analytics, and the broader InformatiX strategy. His focus will be connecting global teams and turning patient and procedure information into actionable clinical insight. Carls brings over 30 years of experience in spine and medical technology. He previously served as vice president of product and clinical at Proprio Vision and spent more than two decades at Sofamor Danek and Medtronic. He holds more than 80 patents.

Recently Posted Jobs

Sign up to get curated job recommendations

Alphatec Spine is Hiring for 34 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs